Deep Genomics is a biopharmaceutical company that aims to revolutionize drug development by leveraging expertise in artificial intelligence (AI) to decode RNA biology. The company's proprietary platform, the AI Workbench, enables it to decode the enormous complexity of RNA biology to find novel targets, mechanisms, and molecules that are not accessible through traditional methods. Deep Genomics use this advanced technology to develop steric-blocking oligonucleotides (SBOs) that achieve expression increase for the treatment of genetic disease. Founded in 2015, the company's multidisciplinary team includes expertise in a diverse range of disciplines including those found in a traditional drug company, as well as machine learning, laboratory automation, and software engineering. Deep Genomics is located in Toronto, Ontario and Cambridge, Massachusetts.